LONDON & NEW YORK–(BUSINESS WIRE)–$CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A … [Read more…]
Arcadea expands its position in Brazilian healthcare software with its fourth investment in the sector TORONTO & RIO DE JANEIRO–(BUSINESS WIRE)–Arcadea Group, a preeminent, long-term investor in global software businesses, today announced the acquisition of Sofis, a leading providing of mission-critical software to the Brazilian healthcare sector, focused on hemotherapy and cell therapy. Founded in … [Read more…]
Approval is based on data from the ASCERTAIN-V clinical trial demonstrating that INQOVI in combination with venetoclax met complete response endpoints, with no new safety concerns reported INQOVI is also approved in the U.S. as a treatment for myelodysplastic syndromes and chronic myelomonocytic leukemia PRINCETON, N.J. & TOKYO–(BUSINESS WIRE)–Taiho Oncology, Inc. and Taiho Pharmaceutical Co., … [Read more…]
SCORPIO-PEP is the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure to an infected individual* Ensitrelvir is an investigational oral antiviral that could offer a new approach to preventing COVID-19 by blocking viral replication during the critical window between exposure and COVID-19 … [Read more…]
Industry leaders from across the health ecosystem, including Clue, Ema EQ, Oura, and Willow, will set the first clinically rigorous, transparent standards for AI in women’s health SAN FRANCISCO–(BUSINESS WIRE)–Today marks a major step forward in women’s health as Willow Innovations, Inc. (Willow), the maternal health pioneer that revolutionized the breast-pumping experience, and Ema EQ, … [Read more…]
New organization leverages manufacturing, PBMC isolation, and cryopreservation services across multiple facilities, supporting cell therapy programs from preclinical through commercial supply Core Excellos team retained; existing customer programs to continue without interruption MIAMI–(BUSINESS WIRE)–OrganaBio, LLC (“OrganaBio”), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially … [Read more…]
Medtech leader with deep orthopedic extremities experience enhances board depth as shoulder-focused company advances growth and strategic objectives NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the appointment of Gordon Van Ummersen to its board of directors. “I am pleased to join … [Read more…]
Data expands mechanistic and translational evidence for selective in vivo programming of monocytes and macrophages, potent peripheral B-cell depletion, and a differentiated cytokine profile CAMBRIDGE, Mass.–(BUSINESS WIRE)–Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new pre-clinical data supporting LIB820, the company’s lead in vivo … [Read more…]
Oral‑B and iADH build on four years of action to advance inclusive oral care and whole‑body health 41% of Europeans identify as living with a disability, representing a four‑point increase wave‑on‑wave BARCELONA, Spain–(BUSINESS WIRE)–Oral‑B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the … [Read more…]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A … [Read more…]
